Remove FDA Remove Immunization Remove Medical Schools
article thumbnail

Leveraging innate cell engagers for lymphoma treatment

European Pharmaceutical Review

Finally, Andreas looks at the prospects for antibodies that target the innate immune system in treating both haematological malignancies and solid tumours. Many cancer patients, however, lack a functional innate immune system, and do not have enough functional NK cells. Dr Harstrick received his M.D.

article thumbnail

Almirall/Lilly lebrikizumab offers potential long-term management of atopic dermatitis

pharmaphorum

The FDA granted lebrikizumab Fast Track designation in December 2019. Almirall has previously found state-of-the-art therapies for immune-related inflammatory diseases such as hidradenitis suppurativa, alopecia areata, psoriasis, and vitiligo.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Developing point-of-care CAR T manufacturing

European Pharmaceutical Review

This is especially important due to the two unique toxicities of CAR T cells, namely CRS and the neurology toxicities that subsequently received the term immune effector cell- associated neurotoxicity syndrome (ICANS). Car-t “The living drugs”, immune checkpoint inhibitors, and precision medicine: A new era of cancer therapy.

article thumbnail

Covid-19 vaccine success bolsters nanoparticle drug delivery research

Pharmaceutical Technology

Covid-19 vaccines from Moderna and Pfizer /BioNTech, which use lipid nanoparticles, became the only two FDA-approved vaccines for almost all ages. However, after a period of slow movement in the field, the FDA approved the first nanodrug, Doxil, for Kaposi sarcoma in 1995. This design protects antibodies from the innate immune system.

article thumbnail

Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer

Pharmacy Times

Standard-of-care treatment for patients with ALK fusions is alectinib (Alecensa; Genentech), a TKI that was approved by the FDA in 2024 for adjuvant treatment following tumor resection in patients with ALK-positive NSCLC. They are more common in younger patients and are often associated with a minimal smoking history.

article thumbnail

Progressing personalised cell therapies in oncology

European Pharmaceutical Review

Last month, CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) was the first BCMA-targeted CAR-T cell therapy to be approved for second-line treatment of multiple myeloma by the US Food and Drug Administration (FDA). CAR T Cells: Engineering Immune Cells to Treat Cancer [Internet]. 2 Why does CARVYKTI have potential in multiple myeloma?

article thumbnail

PharmaShots Weekly Snapshots (May 15 - 19, 2023)

PharmaShots

Alimera Acquires Rights from EyePoint Pharmaceuticals to Commercialise Yutiq in the US Date: May 19, 2023 | Tags: Alimera, EyePoint Pharmaceuticals, Yutiq, Iluvien, chronic non-infectious uveitis, US, Pharma Sobi Reports EMA’s Validation of MAA for Efanesoctocog Alfa to Treat Haemophilia A Date: May 19, 2023 | Tags: Sobi, Efanesoctocog Alfa, (..)